B
Brian J. Altman
Researcher at University of Pennsylvania
Publications - 39
Citations - 4523
Brian J. Altman is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Circadian clock & Circadian rhythm. The author has an hindex of 22, co-authored 31 publications receiving 3443 citations. Previous affiliations of Brian J. Altman include Durham University & University of Rochester Medical Center.
Papers
More filters
Journal ArticleDOI
From Krebs to clinic: glutamine metabolism to cancer therapy.
TL;DR: An updated overview of glutamine metabolism and its involvement in tumorigenesis in vitro and in vivo is provided, and the recent potential applications of basic science discoveries in the clinical setting are explored.
Journal ArticleDOI
MYC, Metabolism, and Cancer
TL;DR: Because of the reliance of MYC-driven cancers on specific metabolic pathways, synthetic lethal interactions between MYC overexpression and specific enzyme inhibitors provide novel cancer therapeutic opportunities.
Journal ArticleDOI
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis
Yan Xiang,Zachary E. Stine,Jinsong Xia,Yunqi Lu,Roddy S. O’Connor,Brian J. Altman,Annie L. Hsieh,Arvin M. Gouw,Ajit G. Thomas,Ping Gao,Linchong Sun,Libing Song,Benedict Yan,Barbara S. Slusher,Jingli Zhuo,London L.P.J. Ooi,Caroline G.L. Lee,Caroline G.L. Lee,Anthony A. Mancuso,Andrew S. McCallion,Anne Le,Michael C. Milone,Stephen Rayport,Dean W. Felsher,Chi V. Dang +24 more
TL;DR: It is reported that loss of one copy of Gls blunted tumor progression in an immune-competent MYC-mediated mouse model of hepatocellular carcinoma and small molecule and genetic inhibition of GLS are supported for targeting the tumor cell-autonomous dependence on GLS for cancer therapy.
Journal ArticleDOI
MYC and metabolism on the path to cancer
TL;DR: Understanding the complexity of MYC-mediated metabolic re-wiring in cancers as well as how MYC cooperates with other metabolic drivers such as mammalian target of rapamycin (mTOR) will provide translational opportunities for cancer therapy.
Journal ArticleDOI
MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells
Brian J. Altman,Annie L. Hsieh,Annie L. Hsieh,Arjun Sengupta,Saikumari Y. Krishnanaiah,Zachary E. Stine,Zandra E. Walton,Arvin M. Gouw,Anand Venkataraman,Bo Li,Pankuri Goraksha-Hicks,Sharon J. Diskin,David I. Bellovin,M. Celeste Simon,Jeffrey C. Rathmell,Mitchell A. Lazar,John M. Maris,Dean W. Felsher,John B. Hogenesch,Aalim M. Weljie,Chi V. Dang +20 more
TL;DR: It is reported here that deregulated expression of MYC or N-MYC disrupts the molecular clock in vitro by directly inducing REV-ERBα to dampen expression and oscillation of BMAL1, and this could be rescued by knockdown of REV -ERB.